Open Payments

BOSTON MEDICAL CENTER

Type
Teaching hospital
Where
South Boston, MA
Medicare CCN
220031
Received
$3,586,676 in 298 records, 2019 ($615,903 general, $2,970,773 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment58$615,903
2019Research payment240$2,970,773

By company

CompanyRecordsAmountYears
PFIZER INC.21$1,595,7972019
Janssen Research & Development, LLC33$333,2802019
Merck Sharp & Dohme LLC28$249,6062019
Amgen Inc.1$209,8782019
Gilead Sciences, Inc.18$181,8372019
VERTEX PHARMACEUTICALS INCORPORATED1$100,0002019
KARL STORZ Endoscopy-America28$93,8972019
C. R. Bard, Inc. & Subsidiaries5$88,6572019
Philips North America LLC3$73,5472019
Aurobindo Pharma USA, Inc.1$58,3042019
KLS-Martin L.P.1$50,0002019
ABBVIE INC.15$46,9602019
Conformis, Inc.6$45,8932019
Biogen, Inc.1$42,9442019
Baxter Healthcare1$35,8002019
E.R. Squibb & Sons, L.L.C.2$28,4002019
Roche TCRC, Inc.8$27,5942019
Laminate Medical Technologies inc.4$26,8032019
Olympus Corporation of the Americas4$26,2802019
Roche Diagnostics Operations, Inc.5$26,1462019
GUERBET LLC1$24,3152019
Intercept Pharmaceuticals, Inc.13$20,0692019
Incyte Corporation22$19,5092019
Bayer Healthcare Pharmaceuticals Inc.6$18,0192019
Shire North American Group Inc10$14,0992019
Genentech, Inc.4$13,7122019
Takeda Pharmaceuticals U.S.A., Inc.1$13,6182019
Emergent BioSolutions Inc.1$11,6952019
Bard Peripheral Vascular, Inc.3$11,5642019
Allergan, Inc.4$11,2002019
AstraZeneca UK Limited1$10,7902019
Integra LifeSciences Corporation3$9,2962019
GENZYME CORPORATION2$9,2002019
GE HEALTHCARE2$7,8982019
Boston Scientific Corporation3$7,4662019
Medical Device Business Services, Inc.6$5,0042019
Medline Industries LP1$5,0002019
Exelixis Inc.3$4,6472019
Medtronic USA, Inc.1$4,5792019
Otonomy, Inc.1$4,0042019
Belmont Instrument LLC1$3,6742019
Abbott Laboratories2$2,9902019
Celgene Corporation2$2,5352019
Emmaus Medical, Inc.1$2,5002019
Alexion Pharmaceuticals, Inc.3$1,6502019
Richard Wolf Medical Instruments Corp.1$1,3502019
Novo Nordisk AS1$1,0002019
ROCHE MOLECULAR SYSTEMS, INC.1$8972019
BioFire Diagnostics, LLC4$8422019
Roche Diagnostics Corporation2$6372019

By nature of payment

NatureRecordsAmount
Research payment240$2,970,773
Grant8$444,412
Education28$92,014
Consulting Fee3$45,000
Gift9$17,890
Charitable Contribution4$8,050
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$5,000
Space rental or facility fees (teaching hospital only)1$2,500
Travel and Lodging3$925
Food and Beverage1$108

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Gilead Sciences, Inc.$59,464GrantCash or cash equivalent2019
2019-12-31Philips North America LLC$33,974Research paymentCash or cash equivalentIngenia 3 0T R5 Device, Devices2019
2019-12-31Roche Diagnostics Operations, Inc.$16,786Research paymentCash or cash equivalentCD cobas Reagents Device, Centralized DiagnosticsRD0014692019
2019-12-31KARL STORZ Endoscopy-America$15,779EducationIn-kind items and servicesTELE PACK X LED,CCU/LIGHT SOURCE/MONITOR Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$10,519EducationIn-kind items and servicesTELE PACK X LED,CCU/LIGHT SOURCE/MONITOR Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$8,296EducationIn-kind items and servicesRINSE TUBE ASSEMBLY Device, OTHER MISC2019
2019-12-31KARL STORZ Endoscopy-America$7,325EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12019
2019-12-31KARL STORZ Endoscopy-America$6,074EducationIn-kind items and servicesASM,HEAD,IMAGE1 S,H3-Z, CE Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$5,937EducationIn-kind items and servicesADAPTOR, C'MT, 30MM, CE Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$5,584EducationIn-kind items and servicesHD,TELECAM-C'MT, NTSC, CE Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$4,073EducationIn-kind items and servicesINSERT,SCISSORS,STRAIGHT,DBL Device, LAPAROSCOPY2019
2019-12-31KARL STORZ Endoscopy-America$3,723EducationIn-kind items and services7 FLAT PANEL MONITOR ONLY F/C-MAC, HDMI Device, ANESTHESIOLOGY2019
2019-12-31Belmont Instrument LLC$3,674GiftCash or cash equivalentThe Belmont buddy 2 Blood/Fluid Warmer Device, Blood Warmer2019
2019-12-31KARL STORZ Endoscopy-America$2,826EducationIn-kind items and servicesC-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$2,684EducationIn-kind items and servicesC-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$2,627EducationIn-kind items and services26 inch LED MONITOR Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$2,626EducationIn-kind items and servicesC-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$2,398EducationIn-kind items and servicesTROCAR SIZE 6MM, BLUNT TIP Device, LAPAROSCOPY2019
2019-12-31KARL STORZ Endoscopy-America$2,213EducationIn-kind items and servicesTROCAR, SIZE 6MM Device, LAPAROSCOPY2019
2019-12-31KARL STORZ Endoscopy-America$2,213EducationIn-kind items and servicesTROCAR, SIZE 6MM Device, LAPAROSCOPY2019
2019-12-31KARL STORZ Endoscopy-America$2,003EducationIn-kind items and services7 FLAT PANEL MONITOR ONLY F/C-MAC, HDMI Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$1,742EducationIn-kind items and servicesROLLING POLE STAND FOR TELE PACK X Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$1,053EducationIn-kind items and servicesADAPTOR, C'MT, 30MM, CE Device, VIDEOIMAGING2019
2019-12-31Roche Diagnostics Operations, Inc.$767Research paymentIn-kind items and servicesCD cobas Reagents Device, Centralized DiagnosticsRD0014692019
2019-12-31KARL STORZ Endoscopy-America$728EducationIn-kind items and services26 inch LED MONITOR Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$634EducationIn-kind items and servicesPOLE STAND FOR VIDEO INTUBATION PLATFORM Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$364EducationIn-kind items and servicesC-MAC POWER SUPPLY REPLACEMENT F/8403ZX Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$244EducationIn-kind items and servicesSCOPE HOLDER Device, ANESTHESIOLOGY2019
2019-12-31KARL STORZ Endoscopy-America$162EducationIn-kind items and servicesLIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING2019
2019-12-31KARL STORZ Endoscopy-America$74EducationIn-kind items and servicesINSERT,DISSECT,RIGHT ANGLE,DBL Device, LAPAROSCOPY2019
2019-12-31KARL STORZ Endoscopy-America$50EducationIn-kind items and servicesINSERT,DISSECT,RIGHT ANGLE,DBL Device, LAPAROSCOPY2019
2019-12-31KARL STORZ Endoscopy-America$25EducationIn-kind items and servicesVARIABLE HEIGHT SECONDARY MONITOR STAND Device, VIDEOIMAGING2019
2019-12-30Janssen Research & Development, LLC$11,752Research paymentCash or cash equivalentDARZALEX Biological, OncologyA Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis2019
2019-12-26PFIZER INC.$363,024Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-12-23Janssen Research & Development, LLC$3,298Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-23ABBVIE INC.$895Research paymentCash or cash equivalentM16-1232019
2019-12-19PFIZER INC.$4,225Research paymentCash or cash equivalentA PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT W2019
2019-12-19Bayer Healthcare Pharmaceuticals Inc.$1,625Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2019
2019-12-18Roche TCRC, Inc.$323Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTHE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA2019
2019-12-16Janssen Research & Development, LLC$1,250Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-16Janssen Research & Development, LLC$500Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-16Merck Sharp & Dohme LLC$267Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-12-12Janssen Research & Development, LLC$25,721Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-12-12PFIZER INC.$2,739Research paymentCash or cash equivalentA PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY O2019
2019-12-06Barco, Inc.$187GiftIn-kind items and servicesPS SM 90/264 120W 24V Device, Diagnostic Imaging2019
2019-12-06Barco, Inc.$187GiftIn-kind items and servicesPS SM 90/264 120W 24V Device, Diagnostic Imaging2019
2019-12-04Genentech, Inc.$9,787Research paymentCash or cash equivalentNon-Covered Product Drug, NonePH II OLE OF GDC 0853 IN ERL2019
2019-11-29Merck Sharp & Dohme LLC$16,239Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj2019
2019-11-29Janssen Research & Development, LLC$6,059Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-11-27PFIZER INC.$66,229Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-11-27PFIZER INC.$33,589Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-11-27Intercept Pharmaceuticals, Inc.$1,503Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662019
2019-11-23PFIZER INC.$10,750Research paymentCash or cash equivalentROBO2 ESOE2019
2019-11-22PFIZER INC.$66,702Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-11-21Conformis, Inc.$6,565Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-11-20Gilead Sciences, Inc.$2,112Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra2019
2019-11-18ABBVIE INC.$1,911Research paymentCash or cash equivalentM16-1232019
2019-11-18Bayer Healthcare Pharmaceuticals Inc.$1,460Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2019
2019-11-18Boston Scientific Corporation$516Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTPREEMPT HF2019
2019-11-15Otonomy, Inc.$4,004Research paymentCash or cash equivalent DrugA Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Int2019
2019-11-12Incyte Corporation$10,400Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-11-12Incyte Corporation$4,225Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-11-12Incyte Corporation$2,600Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-11-12Incyte Corporation$1,284Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-11-07GUERBET LLC$24,315Research paymentCash or cash equivalentEfficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging2019
2019-11-05Takeda Pharmaceuticals U.S.A., Inc.$13,618Research paymentCash or cash equivalentENTYVIO Biological, Lower GIEntyvio-Vedolizumab- Long Term Study2019
2019-10-31Janssen Research & Development, LLC$5,015Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-10-29Gilead Sciences, Inc.$65,000Research paymentCash or cash equivalentDetermining the Burden, Heritability, and Clinical Implications of Increased Liver Stiffness from Fatty Liver Disease in2019
2019-10-29Sysmex America, Inc.$217Travel and LodgingCash or cash equivalentXN Series Device, Hematology2019
2019-10-28Emmaus Medical, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentEndari Drug, Sickle Cell2019
2019-10-22Allergan, Inc.$5,000Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR2019
2019-10-22Allergan, Inc.$2,600Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR2019
2019-10-22Allergan, Inc.$2,100Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR2019
2019-10-22Allergan, Inc.$1,500Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICR2019
2019-10-21Janssen Research & Development, LLC$250Research paymentCash or cash equivalentA Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal2019
2019-10-16Intercept Pharmaceuticals, Inc.$3,284Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662019
2019-10-15Merck Sharp & Dohme LLC$1,750Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-10-15Merck Sharp & Dohme LLC$750Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-10-15Merck Sharp & Dohme LLC$250Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-10-11PFIZER INC.$99,817Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-10-09PFIZER INC.$66,703Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-10-09PFIZER INC.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-10-07GENZYME CORPORATION$4,600Consulting FeeCash or cash equivalentFABRAZYME Drug, RARE DISEASE GENETICS2019
2019-10-07GENZYME CORPORATION$4,600Consulting FeeCash or cash equivalentFABRAZYME Drug, RARE DISEASE GENETICS2019
2019-10-07Merck Sharp & Dohme LLC$474Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-10-04Integra LifeSciences Corporation$955Research paymentCash or cash equivalentPRIMATRIX Device, RECON-SKIN AND WOUNDT-PMXDFU-012019
2019-10-02KLS-Martin L.P.$50,000GrantCash or cash equivalent2019
2019-10-02PFIZER INC.$14,790Research paymentCash or cash equivalentA PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT W2019
2019-10-02Genentech, Inc.$1,500Charitable ContributionCash or cash equivalent2019
2019-10-01Celgene Corporation$448Research paymentCash or cash equivalentRPC-1063 Drug(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) (2019
2019-09-30Janssen Research & Development, LLC$13,956Research paymentCash or cash equivalentDARZALEX Biological, OncologyA Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis2019
2019-09-30ABBVIE INC.$895Research paymentCash or cash equivalentM16-1232019
2019-09-30Roche Diagnostics Operations, Inc.$602Research paymentIn-kind items and servicesCD cobas Reagents Device, Centralized DiagnosticsRD0014692019
2019-09-27Janssen Research & Development, LLC$5,015Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-09-24Merck Sharp & Dohme LLC$348Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-09-19Merck Sharp & Dohme LLC$285Research paymentIn-kind items and servicesCharacterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select2019
2019-09-17Merck Sharp & Dohme LLC$15,125Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-09-11Bard Peripheral Vascular, Inc.$2,304GiftIn-kind items and services2019
2019-09-10Bard Peripheral Vascular, Inc.$4,237GiftIn-kind items and services2019
2019-09-09Bard Peripheral Vascular, Inc.$5,023GiftIn-kind items and services2019
2019-09-07Olympus Corporation of the Americas$6,762GrantIn-kind items and servicesOlympus ENT Instruments Device, ENT Products2019
2019-09-06Medical Device Business Services, Inc.$440Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow-up2019
2019-09-06Aesculap, Inc.$348GiftCash or cash equivalent2019
2019-09-05Janssen Research & Development, LLC$877Research paymentCash or cash equivalentDARZALEX Biological, OncologyA Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis2019
2019-09-05Janssen Research & Development, LLC$539Research paymentCash or cash equivalentDARZALEX Biological, OncologyA Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis2019
2019-09-03Boston Scientific Corporation$450Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTPREEMPT HF2019
2019-09-02Janssen Research & Development, LLC$750Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-08-30PFIZER INC.$99,817Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-08-30PFIZER INC.$66,703Research paymentCash or cash equivalentBIOTHERAPEUTICS TARGETING SLIT2ROBO2 SIGNALING PATHWAY TO TREAT PATIENTS WITH CHRONIC KIDNEY DISEASE AND PROTEINURIA2019
2019-08-30Integra LifeSciences Corporation$8,146Research paymentCash or cash equivalentPRIMATRIX Device, RECON-SKIN AND WOUNDT-PMXDFU-012019
2019-08-30C. R. Bard, Inc. & Subsidiaries$1,800Research paymentCash or cash equivalentARCTIC SUN Device, MEDICAL SYSTEMSINTREPID BMD11112019
2019-08-30ABBVIE INC.$1,791Research paymentCash or cash equivalentM16-1232019
2019-08-29PFIZER INC.$27,674Research paymentCash or cash equivalentDEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERULAR DISEASES SUCH AS FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS 2019
2019-08-29Laminate Medical Technologies inc.$17,706Research paymentCash or cash equivalent Device, BA Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous2019
2019-08-28Merck Sharp & Dohme LLC$82,374Research paymentCash or cash equivalentJANUVIA Drug, ENDOCRINOLOGYEffect of cardiac SGLT inhibition on cardiac energetics and hemodynamic function in type II diabetes2019
2019-08-28Conformis, Inc.$1,911Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-08-27Exelixis Inc.$4,500Research paymentCash or cash equivalentCabozantinib Drug, OncologyRandomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor2019
2019-08-27Intercept Pharmaceuticals, Inc.$2,051Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662019
2019-08-27Exelixis Inc.$122Research paymentCash or cash equivalentCabozantinib Drug, OncologyRandomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor2019
2019-08-27Exelixis Inc.$25Research paymentCash or cash equivalentCabozantinib Drug, OncologyRandomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumor2019
2019-08-26Janssen Research & Development, LLC$4,836Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-08-22C. R. Bard, Inc. & Subsidiaries$16,434Research paymentCash or cash equivalentARCTIC SUN Device, MEDICAL SYSTEMSINTREPID BMD11112019
2019-08-22Roche TCRC, Inc.$7,704Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTHE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA2019
2019-08-22Roche TCRC, Inc.$2,600Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTHE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA2019
2019-08-22Roche TCRC, Inc.$1,584Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTHE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA2019
2019-08-22Roche TCRC, Inc.$1,178Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTHE EFFECT OF 24WEEK TREATMENT WITH BASMISANIL ON COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA2019
2019-08-21Gilead Sciences, Inc.$2,748Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra2019
2019-08-20Merck Sharp & Dohme LLC$16,239Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-08-20Medical Device Business Services, Inc.$1,911Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow-up2019
2019-08-15Intercept Pharmaceuticals, Inc.$750Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662019
2019-08-15Janssen Research & Development, LLC$250Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-08-14Conformis, Inc.$9,750Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-08-12Bayer Healthcare Pharmaceuticals Inc.$2,885Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2019
2019-08-09Janssen Research & Development, LLC$250Research paymentCash or cash equivalentA Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal2019
2019-08-09Janssen Research & Development, LLC$250Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-08-08Acorda Therapeutics, Inc$318Research paymentCash or cash equivalentA 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 Levodopa Inhalation Powder in Park2019
2019-08-08Incyte Corporation$171Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$171Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$133Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$103Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$85Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$61Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$53Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$52Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$28Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$25Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$21Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$21Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$21Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$15Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$10Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$10Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$10Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-08Incyte Corporation$1Research paymentCash or cash equivalentA Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin2019
2019-08-06PFIZER INC.$27,674Research paymentCash or cash equivalentDEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERULAR DISEASES SUCH AS FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS 2019
2019-08-06ABBVIE INC.$2,854Research paymentCash or cash equivalentM16-1232019
2019-08-06Medical Device Business Services, Inc.$943Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow-up2019
2019-08-06ABBVIE INC.$877Research paymentCash or cash equivalentM16-1232019
2019-08-06ABBVIE INC.$582Research paymentCash or cash equivalentM16-1232019
2019-08-06ABBVIE INC.$351Research paymentCash or cash equivalentM14-7482019
2019-08-01Janssen Research & Development, LLC$4,278Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-08-01Shire North American Group Inc$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2019
2019-08-01Shire North American Group Inc$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2019
2019-08-01Shire North American Group Inc$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2019
2019-08-01Shire North American Group Inc$452Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2019
2019-07-31Conformis, Inc.$877Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-07-30ABBVIE INC.$895Research paymentCash or cash equivalentM16-1232019
2019-07-29Merck Sharp & Dohme LLC$16,239Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-07-25Bio-Rad Laboratories, Inc.$22GiftCash or cash equivalentPlatelia Device, Immunoenzymatic2019
2019-07-22Gilead Sciences, Inc.$250Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boo2019
2019-07-18Intercept Pharmaceuticals, Inc.$1,372Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662019
2019-07-18Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-07-11C. R. Bard, Inc. & Subsidiaries$442Research paymentIn-kind items and servicesARCTIC SUN Device, MEDICAL SYSTEMSINTREPID BMD11112019
2019-07-08Gilead Sciences, Inc.$975Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of FTC/TAF and2019
2019-07-05Janssen Research & Development, LLC$11,113Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-07-03Merck Sharp & Dohme LLC$191Research paymentIn-kind items and servicesPIFELTRO Drug, INFECTIOUS DISEASEPhase I,II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine MK-1439 and Doravirine,Lamivudine,Tenofo2019
2019-07-01PFIZER INC.$48,868GrantCash or cash equivalent2019
2019-07-01Shire North American Group Inc$7,709Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2019
2019-06-30Roche Diagnostics Corporation$290Research paymentIn-kind items and servicesCD cobas Reagents Device, Centralized DiagnosticsRD0014692019
2019-06-27Baxter Healthcare$35,800Consulting FeeCash or cash equivalentIPS - Liquid Premix Biological, Integrated Pharmacy Solutions2019
2019-06-27Janssen Research & Development, LLC$1,750Research paymentCash or cash equivalentA Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal2019
2019-06-27ABBVIE INC.$1,535Research paymentCash or cash equivalentM16-1232019
2019-06-26Merck Sharp & Dohme LLC$300Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2019
2019-06-26Merck Sharp & Dohme LLC$300Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid2019
2019-06-26Merck Sharp & Dohme LLC$300Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2019
2019-06-22Olympus Corporation of the Americas$13,523GrantIn-kind items and servicesOlympus ENT Instruments Device, ENT Products2019
2019-06-19Gilead Sciences, Inc.$1,056Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra2019
2019-06-13Alexion Pharmaceuticals, Inc.$150Research paymentCash or cash equivalentSingle Arm Study of ALXN1210 in Complement Inhibitor Treatment-Nave Adult and Adolescent Patients With Atypical Hemolyti2019
2019-06-03Medical Device Business Services, Inc.$390Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow-up2019
2019-05-30Philips North America LLC$35,811Research paymentCash or cash equivalentUS Undivided Serv Device, Cardiology/Vascular DiseasesVM6.02019
2019-05-29Gilead Sciences, Inc.$5,480Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Do2019
2019-05-29ABBVIE INC.$895Research paymentCash or cash equivalentM16-1232019
2019-05-28Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-05-27Janssen Research & Development, LLC$18,310Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2019
2019-05-23Bayer Healthcare Pharmaceuticals Inc.$1,625Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2019
2019-05-23Intercept Pharmaceuticals, Inc.$1,046Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662019
2019-05-23Merck Sharp & Dohme LLC$213Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-05-22Gilead Sciences, Inc.$5,226Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boo2019
2019-05-22Merck Sharp & Dohme LLC$2,120Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2019
2019-05-22Gilead Sciences, Inc.$1,056Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra2019

The latest 200 records of 298.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In Massachusetts; placed by its state only.

MeasureState
Massachusetts
Population B010037,044,056
Population, 2020 census P17,029,917
Median age B0100240.0
Under 18 B0100119.4%
65 and over B0100117.9%
Households B110012,785,042
Foreign born B0500218.0%
Median household income B19013$103,960
Median family income B19113$131,675
Per capita income B19301$57,897
Poverty rate B1700110.0%
Unemployment rate B230255.2%
Civilian labor force B230253,911,446
Mean commute (minutes) B0801329.1
Bachelor's degree or higher B1500347.3%
Housing units B250013,030,406
Owner-occupied B2500362.5%
Renters B2500337.5%
Median home value B25077$562,100
Median gross rent B25064$1,762
White, not Hispanic B0300266.6%
Black B030026.4%
Hispanic or Latino B0300213.3%
Asian B030027.3%
American Indian and Alaska Native B030020.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.